CLB

Core Laboratories faced continued headwinds in Q3 2026, with revenue declining year over year and operating margins pressured by persistent geopolitical conflicts in the Middle East and Eastern Europe.

Core Laboratories just reported Q3 2026 results and the instant verdict from the market has been almost a shrug. The stock is trading near US$10.40, only fractionally above the prior close, even after the numbers hit.

Oilfield services company Core Laboratories (NYSE:CLB) met Wall Street’s revenue expectations in Q3 2026, but sales fell by 1.8% year on year to $132.1 million. Its non-GAAP profit of $0.16 per share was in line with analysts’ consensus estimates.

Core Laboratories (NYSE:CLB) reported higher third-quarter revenue, operating income and earnings per share from the prior quarter, while geopolitical disruptions in the Middle East and Russia-Ukraine continued to constrain parts of its international services…

Core Laboratories (CLB) delivered earnings and revenue surprises of -5.88% and +0.84%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

HOUSTON (AP) — HOUSTON (AP) — Core Laboratories Inc. (CLB) on Wednesday reported profit of $5.

Oilfield services company Core Laboratories (NYSE:CLB) met Wall Street’s revenue expectations in Q3 2026, but revenue fell by 1.8% year on year to $132.1 million. Its non-GAAP profit of $0.16 per share was in line with analysts’ consensus estimates.

Oilfield services company Core Laboratories (NYSE:CLB) will be reporting results this Wednesday after market hours. Here’s what to look for.

If you had decided on 1 January 2026 to sit out Core Laboratories while others debated its international upside, the missed opportunity might feel easier to accept today.

Looking back on oilfield services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Core Laboratories (NYSE:CLB) and its peers.